Is Takeda Pharmaceutical Company Limited (TAK) Overvalued?
We dive into why Takeda Pharmaceutical Company Limited (TAK) could be considered overvalued on 2026-07-16, based on AAII’s Value Score and Grade.Tudor Pop
Stock Evaluator: Takeda Pharmaceutical Company Limited (TAK)
Takeda Pharmaceutical Company Limited TAK
$17.15
-0.11
-0.61%
July 31, 2026 12:01:29 PM
EST
Volume: 1,826,472
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NYSE | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Pharmaceuticals |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Takhzyro, Advate, Elaprase, Replagal, Vpriv, Adynovate/Adynovi, Livtencity, ADZYNMA, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Flexbumin, Adcetris, Leuplin/Enantone, Ninlaro, Iclusig, FRUZAQLA, Alunbrig, vyvanse/elvanse, Trintellix, and QDENGA brands. It has licensing and collaboration for the development and commercialization of products with Arrowhead Pharmaceuticals, Cour Pharmaceuticals, Engitix, Halozyme, Mirum Pharmaceuticals, Ucsd/Fortis Advisors, Zedira/Dr. Falk Pharma, Ac Immune, Acurastem, Anima Biotech, Biomarin, Denali Therapeutics, Luxna Biotech, Neurocrine Biosciences, Peptidream, Abbvie, Adimab, Ascentage Pharma, Crescendo Biologics, Exelixis, F-Star, Gsk, Heidelberg Pharma, Innovent Biologics, Keros Therapeutics, Kumquat Biosciences, Protagonist Therapeutics, Halozyme, Kamada, Johnson & Johnson/Momenta Pharmaceuticals, Previpharma, Novavax, Bridgene Biosciences, Charles River Laboratories, Iambic Therapeutics, Ipsen, Km Biologics, Massachusetts Institute Of Technology, and Nabla Bio. The company operates in Japan, the United States. Europe, Canada, Latin America, China, Asia, Russia/Commonwealth of Independent States, the Middle East, Oceania, and Africa. The company was founded in 1781 and is headquartered in Chuo, Japan.
Commentary & Analysis
Why Takeda Pharmaceutical Company Limited’s (TAK) Stock Is Down 5.23%
As of Thursday, October 30, Takeda Pharmaceutical Company Limited’s TAK share price has dipped by 5.23%, which has investors questioning if this is right time to buy.Jenna Brashear
Is Takeda Pharmaceutical Company Limited(TAK) Building Momentum?
With data as of July 15, 2025, we examine if Takeda Pharmaceutical Company Limited(TAK) is consistently building momentum based on AAII's A+ Investor Momentum and Value Scores and Grades.Omar Beirat
Why Takeda Pharmaceutical Company Limited’s (TAK) Stock Is Down 5.08%
As of Thursday, May 08, Takeda Pharmaceutical Company Limited’s TAK share price has dipped by 5.08%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
3 Undervalued Pharmaceuticals Stocks for Thursday, April 17
Discover the top 3 undervalued Pharmaceuticals stocks for Thursday, April 17 based on AAII’s Stock Grades.Tudor Pop
Financial Summary
| Share Statistics | TAK | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $55,829.3 | $569.9 | 94% |
|
| Shares Out (Mil) | 9.9 | 44.8 | 20% |
|
| Institutional Ownership | 99.7% | 84.6% | 93% |
|
| Float (Mil) | 1,545.3 | 45.1 | 94% |
|
| Beta | 0.09 | 0.67 | 8% |
|
| Avg Daily Volume (000s) | 4,425 | 294 | 91% |
|
| Price Change (52-week) |
20.5% | 65.2% | 62% |
|
| Growth | TAK | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (0.4%) | 6.7% | 16% |
|
| Net Income (5yr) | (17.9%) | (2.0%) | 22% |
|
| EPS (5yr) | (17.9%) | 14.9% | 15 |
|
| Dividends (5yr) | (5.0%) | 0.0% | 83% |
|
| Cash Flow (5yr) | (8.7%) | (14.9%) | 59% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | TAK | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $28,337 | $230 | 94% |
|
| Net Income (TTM) (Mil) | ($958) | ($11) | 1% |
|
| EPS (TTM) | ($0.608) | ($0.600) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | $6,550 | ($6) | 96% |
|
| Net Cash Flow (TTM) (Mil) | $1,451 | $4 | 96% |
|
| Long-Term Debt (Q1) (Mil) | $30,809 | $7 | 97% |
|
| Enterprise Value (Q1) (Mil) | $81,251 | $493 | 95% |
|
| Valuation | TAK | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.58 | 2.89 | 10% |
|
| P/E | na | 20.6 | na |
|
| Dividend Yield | 3.6% | 0.0% | 88% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | TAK | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 64.1% | 65.9% | 76% |
|
| Net Margin | (3.4%) | (0.2%) | 27% |
|
| ROA | (1.0%) | (25.5%) | 36% |
|
| ROE | (2.1%) | (21.4%) | 34% |
|
| Liabilities to Assets | 52.1% | 35.5% | 44% |
|
| F-Score | 4 | 3 | 34% |
|
Takeda Pharmaceutical Company Limited did not pass any screens on 7/30/2026.
